MSPharma

MSPharma is a pharmaceutical company focused on the development, manufacturing, and distribution of a wide array of healthcare products to meet diverse medical needs. Founded in 1989 and headquartered in Amman, Jordan, MSPharma develops and distributes pharmaceutical products, including prescription and over-the-counter medications. In May 2026, Olayan Group invested in MSPharma. Financial terms were not disclosed.

MSPharma specializes in a comprehensive range of pharmaceutical products, including prescription medications, over-the-counter drugs, and specialized therapies targeting chronic and acute conditions such as cardiovascular diseases and pain management. The company serves healthcare providers, hospitals, and pharmacies, primarily in the Gulf Cooperation Council (GCC), North Africa, and the Levant region, emphasizing quality and innovation to provide reliable treatment options. MSPharma generates revenue through direct sales to healthcare institutions and partnerships with wholesalers and distributors. The company engages in B2B transactions, supplying products to hospitals and pharmacies, with revenue streams from both prescription and over-the-counter products.

Their flagship products significantly contribute to sales, supported by strong client relationships and consistent product availability. MSPharma plans to introduce new products designed to meet emerging healthcare needs, with details on release dates to be announced. The company aims to expand into additional markets, particularly in new regions of the Gulf Cooperation Council and North Africa. The recent funding will be allocated to support these product launches and market expansion initiatives.